Tier 2 — strong

Betaine supplementation improves CrossFit performance and increases testosterone levels, but has no influence on Wingate power: randomized crossover trial

Emilia Zawieja, Krzysztof Durkalec-Michalski, Marcin Sadowski, Natalia Główka, Agata Chmurzynska
Journal of the International Society of Sports Nutrition 2023 20(1):2231411

Bibliography

PubMed
PMID 37409757
PubMed Central
PMC10327519
Funding
Reported funding/support: funded by 2017/27/N/NZ9/00750The present research was funded by the Polish National Science Centre under Grant no. 2017/27/N/NZ9/00750.
Competing interests
Reported disclosure: No potential conflict of interest was reported by the author(s).

Study snapshot

DesignRandomized crossover controlled trial
ModelHuman participants
Sample43 CrossFit practitioners completing the protocol
InterventionBetaine 2.5 or 5 g/day versus placebo
Duration3 weeks per treatment
EndpointsCrossFit performance; Wingate power; Testosterone; Body composition

What the study showed, in plain terms

Published in 2023, this source examined exercise performance and body composition. Design: Randomized crossover controlled trial. Sample/model: 43 CrossFit practitioners completing the protocol. The exposure or intervention was Betaine 2.5 or 5 g/day versus placebo. Follow-up or treatment period: 3 weeks per treatment.

Fight Gone Bad performance improved during betaine treatment. Wingate power and body composition did not; no clear dose or MTHFR-genotype interaction emerged.

The testosterone signal was modest and outcome-specific. This paper shares the registered cohort with related cardiometabolic and amino-acid reports. Related reports from the same research program may share participants. Read trial registration and linked companion reports before counting independent studies.

Continue with TMG Data Center

Continue with Betaine Anhydrous Pre-Workout: Performance, Dose and Evidence

Key findings

  • Fight Gone Bad performance improved during betaine treatment.
  • Wingate power and body composition did not; no clear dose or MTHFR-genotype interaction emerged.
  • The recorded outcome domains were CrossFit performance; Wingate power; Testosterone; Body composition.
  • The result applies to the tested exposure: Betaine 2.5 or 5 g/day versus placebo; 3 weeks per treatment.

What this study can and cannot tell us

  • The testosterone signal was modest and outcome-specific. This paper shares the registered cohort with related cardiometabolic and amino-acid reports. Related reports from the same research program may share participants. Read trial registration and linked companion reports before counting independent studies.
  • An individual controlled trial must be interpreted alongside its comparator, sample size, endpoint selection and independent replication. It does not validate a different commercial formulation or a general longevity claim.
  • Source basis: Accessible full-text extract plus indexed bibliographic data. Missing method details, funding information or participant denominators are not inferred.

Citation network

Articles citing this research paper

4 articles

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified